Experimentation on human stem cells is hampered by the relative paucity of this population and by the lack of assays identifying multilineage dflerentiation. particularly along the lymphoid lineages. In our current study, phenotypic analysis of low-density fetal bone marrow cells showed two distinct populations of CD34+ cells: those expressing a high density of CD34 antigen on their surface (CD34h') and those expressing an intermediate level of CD34 antigen (CD34"). Multiple tissues were used to characterize the in vitro and in vivo potential of these subsets and showed that only CD34h' cells support long-term B lymphopoiesis and myelopoiesis in vitro and mediate T, B, and myeloid repopulation of human tissues implanted into SCID mice. CD34" cells re-URING FETAL DEVELOPMENT, blood cells are derived from a limited pool of hematopoietic stem cells present in fetal liver and bone marrow. Primitive stem cells are extremely rare (<0.01%) in bone marrow, but can be distinguished by their high proliferative potential and possibly by their ability to ~e1f-renew.I.~ However, our understanding of the ability of human stem cells to mediate longterm multilineage reconstitution is limited in two ways. First, most in vitro assays for these cells address predominantly the myelo-erythroid potential of candidate populations. Undoubtedly, both the lymphoid and myeloid potential of stem cells is important when considering transplantation of extensively purged bone marrow into severely immunocompromised patients. Second, very few cells are isolated in multiparameter fractionation schemes, limiting the scope of investigation for any given tissue.
URING FETAL DEVELOPMENT, blood cells are derived from a limited pool of hematopoietic stem cells present in fetal liver and bone marrow. Primitive stem cells are extremely rare (<0.01%) in bone marrow, but can be distinguished by their high proliferative potential and possibly by their ability to ~e1f-renew.I.~ However, our understanding of the ability of human stem cells to mediate longterm multilineage reconstitution is limited in two ways. First, most in vitro assays for these cells address predominantly the myelo-erythroid potential of candidate populations. Undoubtedly, both the lymphoid and myeloid potential of stem cells is important when considering transplantation of extensively purged bone marrow into severely immunocompromised patients. Second, very few cells are isolated in multiparameter fractionation schemes, limiting the scope of investigation for any given tissue.
Several groups have shown that the CD34 antigen marks all human myeloid and erythroid progenitor cells5"' and that this population can mediate rapid engraftment of an immunocompromised host in vivo.".'2 The expression of CD34 is lost with hematopoietic differentiati~n.'~ For instance, it has been shown, both by phenotypic analysis and by direct differentiation studies, that the CD34 molecule present on intrathymic T-cell precursors is downregulated with T-cell matuAlthough immature, the CD34+ cell population still contains heterogeneous progenitors at various stages of differentiation.I6 In the past few years, several schemes by which CD34+ cells can be fractionated into lineage-committed and noncommitted progenitors have been rep~rted.~"~".'"~ Isolation of cells expressing high levels of CD34 has been used to evaluate multipotent hematopoietic activity.17.21-23 However, our own experience has shown that using a fixed percentage of the brightest CD34+ cells as a fractionation criterium fails to provide a consistent and reliable definition of multipotent hematopoietic progenitor cells. Additionally, very little is known about the comparison of CD34-bright cells with the remaining CD34-dim counterpart, particularly in fetal bone marrow. We therefore felt it was important to examine the relative stem cell content of fetal bone marrow based on density of CD34 antigen expression on the cell surface.
We herein describe the isolation and characterization of peatedly failed to provide long-term hematopoietic activity in vivo or in vitro. These results indicate that a simple fractionation based on well-defined CD34 antigen levels can be used to reproducibly isolate cells highly enriched for in vivo long-term repopulating activity and for multipotent progenitors, including T-and B-cell precursors. Additionally, given the limited variability in the results and the high correlation between in vitro and in vivo hematopoietic potential, we propose that the CD34"' population contains virtually all of the stem cell activity in fetal bone marrow and therefore is the population of choice for future studies in hematopoietic stem cell development and gene therapy. two distinct populations of CD34+ cells, ie, those expressing high levels of the antigen (CD34hi) and those expressing lower levels of antigen (CD34'"). We adopted an experimental strategy correlating in vitro activities of human hematopoietic cells with experimental in vivo models using SCID mice,lg which we speculate have important clinical rele~a n c e . '~ We now show that all of the primitive multilineage potential (henceforth stem cell activity) in fetal bone marrow is confined to the CD34" compartment. This population represents the optimum combination of purity and yield of stem cells from fetal bone marrow and is well suited for experiments aimed at understanding the early events of hematopoietic differentiation into both lymphoid and myeloid lineages.
PE-conjugated MoAbs to glycophorin A (D2.10) and CD38 (T16) were purchased from AMAC (Westbrook, ME). CDla (RT6) was purchased from Coulter (Hialeah, FL). Tricolor (TC)-conjugated anti-CD45, -CD& and -CD3 were purchased from Caltag (South San Francisco, CA . This incubation was also followed by three washes in SB. Cells were resuspended in SB containing 1 pg/mL propidium iodide (Molecular Probes Inc. Eugene, OR) and sorted using the FACStar plus cell sorter (Becton Dickinson, San Jose, CA). Live cells (ie, those excluding propidium iodide) were always greater than 95%. Live cells that were Lin-were sorted according to levels of CD34 expression. Sort gates were set based on the mean fluorescence intensity of the isotype control sample. All cells with CD34 values between 10 and 100 times the mean fluorescence intensity (MFI) of the isotype control were sorted as CD34'". Those cells with CD34 MFI greater than 100 times the MFI of the isotype control were sorted as CD34h'. Cells were collected in 24-or 48-well plates in RPMI containing 10% FCS and 10 mmoVL HEPES, counted, and reanalyzed for purity in every experiment.
Phenorypic analysis of sorted fetal bone marrow. Bone marrow samples were stained and sorted as described above. Sorted cells (20,000 to 50,000) were restained with a panel of PE-or FITCconjugated MoAbs as described and then reanalyzed. A portion of each sorted population was incubated with the appropriate isotype control to establish the background level.
In vitro coculture. Sorted cells were cultured by limit dilution and/or single-cell deposition on a pre-established monolayer of a mouse stromal cell line (Sys-l) as previously described." Briefly, 1 x IO4 Sys-l stromal cells were plated in 96-well flat-bottom plates 1 week before the experiment in 100 pL of medium consisting of 50% Iscove's modified Dulbecco's medium (IMDM; JRH Biosciences), 50% RPMI with 10% FCS, 4 X moVL 2-mercaptoethanol, 10 mmol/L HEPES, penicillin (100 U/mL) and streptomycin (100 mg/mL) (P/S), and 4 mmoVL glutamine (JRH Biosciences). Serial dilutions of sorted cells were added to stromal cells in a 100 pL volume per well. For limit dilution analysis, 12 to 24 wells of each cell concentration were plated per population at 4 to 8 cell concentrations ranging from 1,000 cells per well to 33 cells per well in 200 pL final volume. Medium was replaced weekly by demidepletion. Plates were visually scored from weeks 4 through 6 for the presence of tightly formed clusters of small cells (cobblestone areas), as previously des~ribed.~~.'~ Wells with dispersed cells or only large vacuolar cells were counted as negative. Linear regression analysis was used to determine the frequencies of the 4-to 6-week cobblestone area-forming cells among sorted populations in a manner similar to that described for clonal analysis of other effector cells?' SCID-hu bone assay. C.B-17 scidscid (SCID) mice were bred in our facilities under sterile conditions and protected by antibiotic treatment in drinking water. Mice used were between 6 to 8 weeks of age and the construction of SCID-hu bone mice was as previously described?' Briefly, fetal long bones were split lengthwise and bisected to yield 4 fragments per bone. One or two bone fragments were immediately implanted subcutaneously into the mammary fat pads of SCID mice under anesthesia of methoxyflurane vapors and intramuscular injection of a mixture of ketamine hydrochloride (50 mgikg) and xylazine hydrochloride (25 mgikg).
A sample of the fetal tissue was stained with a panel of MoAbs to HLA to establish host bone allotype. SCID-hu bone mice were used 5 to 12 weeks postimplantation as recipients for HLA-mismatched sorted cell populations. Immediately before cell injection, SCID-hu bone mice received a single whole body irradiation dose (350 rad from a "' CS source; Gamma Cell 40; J.L. Shepherd & Associates, San Fernando, CA). Sorted cells (1.5 to 5 X IO4) were then injected directly into the bone using a Hamilton syringe in a 10 pL volume. SCID-hu bone mice were kept for 5 to 9 weeks and then killed. Human bones were removed, adherent tissues were dissected away, and bones were split open to flush the marrow cavity with SB. Collected cells were spun down and the pellet was resuspended for 5 minutes into a red blood cell lysing solution.zx Cells were washed twice in SB and counted before being stained for two-color immunofluorescence with directly labeled MoAbs against HLA allotypes in combination with CD19, CD20, CD33, CD14, or CD34. FITC-and PE-conjugated irrelevant mouse Igs were used as negative controls. Cells were analyzed on a FACScan fluorescent cell analyzer.
SCID-hu thymus assay. As reported previously," 19-to 22-week-old fetal thymi were dissected and fragments containing 2 to 4 intact lobules were placed on nitrocellulose filters (0.8 mm; Costar Corp, Cambridge, MA) on top of gelatin rafts (Gelfoam; Upjohn, Kalamazoo, MI) in RPMI medium containing 10% FCS and P/S. A sample of thymocytes was taken for HLA immunophenotyping of the recipient thymus. After 7 days of incubation at 25°C and 5% CO2, fragments were irradiated with 200 to 600 rad from a "'CS source (JL Shepherd & Associates), washed, and immediately microinjected with 1 x l@ HLA-mismatched sorted cell in a 1 pL volume using an oil-filled micro injector (Narishige, Tokyo, Japan) and 1 mm diameter glass micropipets (World Precision Instruments, Sarasota, FL). Fragments were placed back on the filters and incubated at 3 7 T , 5 % CO2 overnight and then inserted under the kidney capsule of anesthetized 6-to 8-week-old SCID mice. Mice were killed at various times after transplantation and the thymus grafts were recovered, reduced to a cellular suspension, and subjected to three-color immunofluorescence analysis using directly labeled MoAbs with FITC, PE, and TC on the FACScan.
RESULTS
Characterization of the fetal bone marrow progenitor compartment. We sought to define a simple strategy for fractionating fetal bone marrow that resulted in the maximum yield of hematopoietic stem cells for experimentation. Phenotypic analysis of low-density fetal bone marrow cells showed that CD 14+ monocytes, CD 1S+ granulocytes, CD16' granulocytes, and natural killer cells together comprised an average of 40% i 9% of all cells. These markers identified all highly autofluorescent cells and those cells with high orthogonal light scatter. These cells, as well as CD2' T cells, CD20' B cells, and glycophorin A+ erythroblasts, were distributed largely (>90%) into the CD34-compartment of the fetal bone marrow and are associated with mature cells having no long-term in vitro or in vivo hematopoietic activity (Baum et al" and our own observations). However, we found that CD10 and CD19 stained a distinct portion of CD34' cells but none of the cells with the highest density of CD34 on their surface.
CD34' cells can be divided into two distinct populations of cells based on CD34 antigen density ( Fig  1) . Approximately 80% of CD34+ cells stained with an MFI 10-to 100-fold greater than that of the isotype control and are referred to as CD34'". The remaining CD34' cells stained with an MFI greater than 100-fold above the isotype control and are referred to as CD34h'. A total of 1. 5 tissues were analyzed for the percentage of lineage-negative cells that were CD34', CD34-, CD34h', and CD34'" (Lin = CD14, CD15, and CD16 to exclude highly autofluorescent and Fc binding cells without compromising the integrity of the CD34' compartment; Table 1 ). Whereas the percentage of cells that occupied the CD34h' and CD34'" compartment varied (4.6% 2 3.5% and 21% i 6.6'31, respectively), the average staining intensities were very reproducible. An analysis of 9 individual fetal bone marrow samples showed that the low-density mononuclear cells stained with the IgG3 isotype control had a mean channel value of 9 ? 4, and that cells in the CD34'" or CD34h' regions had mean channel values of 172 ? 67 and 972 2 291, respectively. The difference between the mean channel value for CD34 staining and the isotype was at least 2 logs for CD34h' and below 1.5 logs for CD34'" cells in most tissues.
We then compared a variety of methods to stain fetal bone marrow cells to determine whether the staining patterns might vary with the anti-CD34 antibody used and the type of fluorochrome, and whether the staining was direct or indirect as shown. We investigated the use of a biotinylated Fab; fragment of the Tuk-3 antibody (detected with Red670 avidin), of a PerCp conjugate of Tuk-3, and of a different clone of anti-CD34 antibody, HPCA-2 (clone 8G12), conjugated to phycoerythrin (Fig 2) . A clear distinction between CD34h' cells and CD34'" cells was also observed using these methods, although the level of resolution was compromised using the PerCp direct conjugate. Staining fetal bone marrow with an anti-CD34 antibody directed against an epitope distinct from HPCA-2 and Tuk-3, Qbend 10; also subdivided the whole CD34 compartment into CD34h' and CD34'" cells (Dr B. Hill, Systemix, personal communication, 1993).
To evaluate the distribution of hematopoietic progenitor activity in the CD34hi and CD34'" cells, the purity of sorted populations was measured. On the average, recoveries of cell populations by flow cytometry sorting ranged from 43% to 62%, with typical harvests of 1 to 2 X lo6 CD34h' cells and greater than 4 X lo6 CD34'" cells per donor tissue (one set of 6 long bones). A sample of the sorted cells was reanalyzed immediately after sorting to measure the purity before assays, and routinely found to be greater than 90% pure with respect to contamination from CD34-or Liin+ cells. Additionally, the Overton cumulative subtraction methodz9 was used to assess the level of cross-contamination of CD34h' with CD34'" cells (Fig 3) . These measurements consistently gave us an estimate of 85% to 90% purity; therefore, we expected 10% to 15% contamination of CD34" with CD34h' and vice versa. These measurements proved important for quantitative studies on populations with high proliferative potential, as described below.
Phenotypic analysis of sorted CD34h' and CD34" populutions. Sorted CD34h' and CD34'" cells demonstrated differential expression of a limited panel of cell surface antigens (Fig 4) , the most interesting of which was the distribution of CD38, CD45RA, CD19, and CD10 molecules. The CD34'" population clearly contains subsets of CD10' (47%) and CD19+ (20%) cells that are probably pre-B cells,30 whereas these markers are absent on CD34K cells. Most CD34h' cells express low levels of CD13 and CD33, suggesting that they are predominantly early myeloid progenitors. When compared with the CD34'" population, the CD34h' subset is enriched in cells expressing low levels of CD38 (42% v 1%) and of CD45RA (59% v 39%) and, to a lesser extent, negative to low levels of HLA-DR (4% v 2%). The CD34h' population also shows a higher percentage of cells expressing the Thy-l molecule (44% v 26%). Based on our previous observations and work in other laboratories, this staining profile is consistent with the enrichment of cells in the CD34h' compartment with characteristics of hematopoietic stem cells,' .1",17-20.22.31 Forward and orthogonal light scatter analysis for size and granularity respectively show that both populations have low granular content, but are fairly heterogeneous for size, with CD34hi cells displaying a slightly larger forward light scatter and blast cell characteristics (data not shown). Furthermore, staining for CD45 showed that, in both populations, between 95% and 98% of the cells were positive with a strong intensity, precluding contamination with erythrocytes (data not shown). The nature of the non-B-lineage cells of the CD34'" population was not clear from the immunophenotypic analysis and could not be inferred from morphologic examination (data not shown). However, we have observed that CD34'" cells contain a significant number of erythroid progenitors, as determined in traditional clonogenic assays (Dr D. Dalton, personal communication). Thus, phenotypic analysis suggests that CD34hi and CD34'" subsets are distinct cell populations and, although CD34h' cells may largely be committed to myeloid lineages, they are enriched in cells expressing markers for primitive hematopoiesis.
Activity of CD34 subsets in stromal coculture assays. The relative stem cell content of each population was determined by limiting dilution analysis of cells seeded onto Sys-1 monolayers. Individual wells were visually evaluated between weeks 4 and 6 and were considered positive if they contained tightly packed clusters of cobblestone areas as previously described.25226 Table 2 lists the frequencies of cobblestone area-forming cells (CAFC) among various fetal bone marrow populations. Differences were observed in the growth kinetics of individual tissues, but the growth of all populations appewed to decline after 6 weeks of culture. The average frequency of responding cells calculated for the CD34h' subset at 4 weeks is U190 (0.52% 2 0.21%, n = 6), whereas CD34'" cells scored with an average value of l / 3,745 (0.03% ? 0.03%, n = 6), consistent with the readout of 5% to IS% contaminating CD34'" cells as predicted from sort purity analysis. The CD34' population gave an average frequency of 1/646 (0.16% i 0.05%, n = 6). Thus, the CD34hi cell population had a 3.4-fold increase in precursor frequency over CD34' population, which approaches a quantitative recovery of all of the activity of whole bone marrow in the CD34hi compartment. The CD34-and Idin' populations had no activity in this assay. The nature of the progeny of cultured cells was directly examined by cytofluorometric analysis of cultured cells with lineage-specific MoAbs. Positive wells from limit dilution cultures were stained by direct immunofluorescence with antibodies specific for B cells (CD10 and CD19) and myeloid cells (CD15 and CD33), and were analyzed by flow cytometry. Approximately 80% of the wells analyzed contained both B-lymphoid and myeloid cells as determined by cell surface antigen expression (Fig 5) . These results suggest that CD34'" cells contain virtually all of the long-term coculture activity of fetal bone marrow and that the maintenance of cobblestone areas in our coculture assay indicates the presence of primitive and multipotent hematopoietic progenitors.
I n vivo reconstitution of human bone frugments. Human fetal bone fragments were implanted in SCID mice for a minimum of 5 weeks before subjecting them t o total body irradiation to deplete the implanted bones of hematopoietic cells. Because SCID mice have an increased sensitivity to irradiation due to DNA repair defects,i2 preliminary experiments determined the dose of irradiation (350 rad) needed to successfully ablate hematopoiesis into the human bones while maintaining virtually 100% of the animals alive. An extended lineage panel including CD2, CD20, and glycophorin A was used in the sorts for in vivo assays to deplete cells potentially responsible for allogeneic reactions. As mentioned earlier in the text, CD2+, CD20', and glycophorin A' cells were exclusively contained in the CD34-compartment; therefore their removal did not compromise the composition of the CD34"' and CD34'" subsets as defined in Table 1 . Immediately after irradiation, sorted HLA-mismatched CD34h' and CD34'" cells were directly injected into the bone cavity. After 5 to 9 weeks, human bones were retrieved and analyzed using two-color immunofluorescence. Staining for HLA class I-positive leukocytes (W6/32+ and CD457 was used to calculate the percentage of human cells in each graft. Stainings with antibodies specific for an HLA polymorphic determinant of donor cells (donor-HLA) and W6/32 or lineage-specific markers were used to calculate the level of donor reconstitution in the grafts. Table 3 shows the results of three separate experiments. The cell numbers retrieved from grafts varied independently of the cell population injected (data not shown). Bones reconstituted with CD34h' cells contained a high proportion of human cells (91% 2 5%), with an average of 67% -+ 27% (ranging from 23% to 99%) donor-derived cells, whereas bones injected with the CD34" subset as well as noninjected bones contained no detectable donor cells and had an average of 68% * 38% and 72% t 34% host-derived human cells, respectively. Bone grafts were analyzed for phenotypic composition. Figure 6 shows a representative graft reconstituted with CD34"' fetal bone marrow cells, retrieved after 9 weeks. Ninety-six percent of the cells are human (Fig 6A) , of which 91% are donor-derived cells (Fig 6B) . Forward (FSC) and side scatter (SSC) analysis of the donor cells shows the typical distribution of a heterogeneous bone marrow population (Fig 6C) . Donor-derived CD20+ cells (Fig 6D; 42% of total sample) and CD19+ cells (Fig 6E; 57% of total sample) were identified and showed the size and granularity characteristics of B cells (Fig 6F) . Similarly, donor-derived CD33+ (Fig 6G; 30% of total sample) and CD14+ (Fig 6H; 11% of total sample) myeloid cells were found with FSC and SSC typical of monocytes (Fig 61) and myeloid cells with high side scatter typical of mature granulocytes (Fig 6J) . Using a different combination of fluorochromes, donor-derived CD34+ (Fig 6K; 14% of total sample) cells were also detectable, and the specificity of the staining was demonstrated with an irrelevant control staining (Fig 6L) .
In sharp contrast, CD34'" cells failed to engraft, and no donor progeny could be identified. Fetal bone marrow CD34-cells were tested and also showed no engraftment. Because of the initial sort purities, these results suggest multilineage differentiation rather than expansion from the CD34" stem cell-containing population. These findings demonstrate the long-term potential of CD34hi cells and closely parallel the in vitro observations confirming that CD34h cells Limiting dilution analysis of sorted fetal bone marrow population was used to establish the frequency (expressed as percentage) of cells that form cobblestone areas between weeks 4 and 6 of culture on a stromal cell line. Some cultures were either lost to contamination or killed for analysis before week 6 (ND). The average response (AVG) and standard deviation (SD) were calculated. The number of cells containing one cobblestone area forming cell is listed as the reciprocal of the average frequency (VAVGI.
contain virtually all of the B and myelopoietic potential associated with fetal bone marrow.
In vivo reconstitution of human fetal thymus. It has been demonstrated that human fetal CD34' cells can reconstitute a depleted allogeneic thymus cultured in vitro or implanted into SCID mice, and generate donor-derived thymocyte^.'^.^^ In contrast to the short-term in vitro culture assays, the SCID mouse model allows maintenance of donor-derived T cells for as long as 4.5 months. A three-color immunofluorescence procedure was used to stain thymocytes recovered from the thymic grafts to assess the quality of donor-derived thymopoiesis by examining the coordinated expression of CDla, CD3 or CD4, and CD8 molecules. Depleted thymic grafts were reconstituted with CD34 subsets from allogeneic fetal bone marrow, and were analyzed after 6 to 14.5 weeks. In 5 different experiments, the vast majority (26 of 32) of the grafts injected with CD34h' cells were recovered, whereas grafts injected with CD34" had degenerated and were rarely recovered (9 of 22). Among the grafts recovered, those injected with CD34"' cells consistently contained donor-derived thymopoiesis, with percentages of T-cell reconstitution ranging from 60% to 100% (Fig 7) .
Further phenotypic analysis (Fig 8) showed that the Tcell progeny of CD34" fetal bone marrow closely resembles that of normal fetal thymi, based on the high expression of CDla, the graded levels of CD3 staining, and the coexpres- sion of CD4 and CD8 on the majority of thymocytes as well as the presence of a small number of CD4 or CD8 singlepositive thymocytes. In contrast, only 1 of the 9 recovered grafts injected with CD341° cells contained donor cells (Fig For 7) and this graft contained only donor-derived mature thymomarrow cells were capable of engrafting an allogeneic thycytes (data not shown). Grafts unsuccessfully reconstituted mus and of generating T cells for sustained periods of time. (ie, injected with CD34'" cells or noninjected) showed the CD34-fetal bone marrow cells were devoid of such pre-Tpresence of host-derived thymocytes exclusively, which cell activity (data not shown). Taken together, these data have completely differentiated into MHC class I bright cells clearly show that :he capacity to generate T, B, and myeloid with high levels of CD3 without CD1 or coexpression of cells is exclusively restricted to the CD34hi compartment of CD4 and CD8 (Fig 8) . Therefore, only CD34hi fetal bone fetal bone marrow. 
DISCUSSION
The presence of primitive hematopoietic cells expressing high-density CD34 has already been rep~rted,'~*~'-*~ particularly in adult bone marrow, where CD34 antigen density decreases concurrently with maturation and increased CD38 cell surface expre~sion.'~ Additionally, we have recently provided direct evidence that CD34 decreases during T-cell development using a short-term in vitro T-cell differentiation assay.I5 However, evidence is lacking to demonstrate that pluripotent stem cells (as defined by their capacity to generate T, B, and myeloid lineages) exclusively resides in the compartment of marrow having the highest levels of CD34 antigen. In our current investigation, high resolution flow cytometric analysis of fetal bone marrow reproducibly showed two distinct populations of CD34+ cells, ie, those expressing high levels of the antigen (CD34") and those expressing lower levels of antigen (CD34'"). These populations can be reproducibly isolated by fluorescence-activated cell sorting, especially if a limited panel of antibodies is used to exclude highly autofluorescent myeloid cells that can be mistaken for antigen-positive cells. We herein demonstrate that the multipotent stem cell activity is exclusively restricted to the CD34hi compartment of fetal bone marrow.
Phenotypic analysis of sorted fetal bone marrow CD34+ cells showed that the CD34K subset was enriched over CD34" for cells with phenotypes that have been reported by other groups to define the most primitive hematopoietic cells such as Thy-l+,'' IUA-DR'0w,'*20*22 CD3810W , 13.17 and CD45RA-.18331 CD34" cells also expressed low levels of antigens found on very early myeloid progenitors (CD13 and CD33) but no detectable cell surface antigens that defined the more mature cells (CD2, CDlO, CD14, CD15, CD16, CD19, or glycophorin A). Alternatively, CD34" cells expressed antigens found on progenitors for B cells (CD10 and CD19) as well as intermediate to high levels of CD38. This differential expression of lineage antigens on CD34 subsets then suggested that the primitiveness of progenitor cells was closely related to levels of CD34 antigen expression and led us to test these populations in functional assays to determine their hematopoietic potential.
Cocultivation of candidate stem cell populations on primary bone marrow stromal cell isolates or bone marrowderived cell lines has been used to demonstrate active hematopoiesis for extended periods of time (8 to 12 lation can be inferred from the maintenance of colony-forming potential in secondary clonogenic assays. However, in vitro assays tend to measure only the myeloid andlor erythroid potential of candidate stem cell populations and demonstration of the differentiation into cells of the lymphoid lineage is often lacking. The relationship between cell surface antigen expression and cellular identity has been reported: ' and was used in this study to assess the presence of lymphoid and myeloid cells. We speculate that, in our in vitro coculture assay, cobblestone areas found after 6 weeks of culture arose from primitive hematopoietic stem cells for several reasons. First, there was no detectable CDlO or CD19 on the surface of CD34hi cells, ruling out the possibility that we were expanding early B-cell progenitors in our starting population. Second, our culture conditions did not support the maintenance of the CDlO and CDl9-positive CD34'" population over the 6 weeks of culture and thus the expansion of contaminating lineage-committed progenitors is unlikely. Third, experiments designed to test clonogenic potential of CD34hi population showed B and myeloid cells in up to 5% of wells seeded with single cells and showed the maintenance of cells with a CD34"Lin-phenotype that have been used to reinitiate long-term cultures (M. Backer, J. Young, D. DiGiusto, manuscript in preparation). Finally, long-term B lymphopoiesis and myelopoiesis were confirmed using the SCID-hu bone model and correlated well with T lymphopoiesis potential in the SCID-hu thymus assay.
Differentiation of candidate human stem cell populations into the T-cell lineage has been infrequently reported. Reviously, we have shown that triple-negative (CD3-, CD4-, CDS-) thymocytes express the highest levels of CD34 in the thymus and differentiate into CD4+ CD3-CD8-pre-T cells displaying lower levels of CD34 and then into CD4+ CD8+ double-positive and mature thymocytes that no longer express CD34.l' Using the SCID-hu mouse model, we were able to examine long-term T lymphopoiesis, and observed the generation of immature CDla+, double-positive thymocytes for periods of 12 to 15 weeks. In SCID mice, thymic tissue alone engrafts poorly and generally no longer produces immature thymocytes (CDl+) past 6 ~e e k s~~.~~ (our own observations), unless a source of progenitors is added in the form of a fetal liver fragment or of microinjected CD34+ ~e l l s .~~,~' Reconstitution studies in mouse have shown that stem cells can differentiate into T cells if directly injected into the thymus?8 Therefore, in the SCID-hu thymus assay, the long-term persistence of donor-derived immature thymopoiesis is compatible with the read-out of a stem cell from the CD34" fetal bone marrow population. 
CD4
Human fetal bones implanted in the immunodeficient SCID mice can sustain active hematopoiesis in vivo for as long as 20 weeks,28 which indicates that human bones implanted into SCID mice can provide an in vivo microenvironment sufficient for the maintenance and differentiation of human stem cells. In our SCID-hu bone assay, we were able to observe differentiation of CD34hi cells into multiple lineages for at least 9 weeks. At this time point, the persistence of granulocytes, which have a short half-life, is strongly indicative of the ongoing production of progenitors generated from stem cells. In addition, donor-derived CD34+ cells were maintained in these bones. These in vivo assays have not succumbed to allogeneic barriers leading to graft failures, and are fit for the study of human allogeneic stem cell transplantation, reinforcing the notion that SCID-hu mice are invaluable preclinical models.24328 Therefore, the multilineage differentiation of CD34& cells into CD33' myeloid progenitors, and CD19+ or CD20+ B cells, and into CD3+ CDl+ CD4+ CD8+ T cells for up to 8 weeks of culture and in the in vivo SCID-hu bone and SCID-hu thymus assays, is of significant importance and strongly suggests that this population contains primitive hematopoietic stem cells.
Although our data indicate that all of the stem cell activity
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From is recovered in the CD34hi subset, frequency estimates in vitro show that few of CD34hi cells are actually stem cells. Limiting dilution analysis of CD34hi cells on murine stromal cells showed that the stem cell (CAFC) activity was contained in about 0.5% to 1% of CD34hi cells, which represents a 100-fold increase over whole bone marrow and a threefold to fivefold increase over CD34+ cells. In contrast to similar assays on adult hematopoietic progenitor cells,17~1s*35 exogenous human growth factors and cytokines were not required for the maintenance of the cultures of fetal hematopoietic cells for periods of up to 8 weeks. This indicates that fetal and adult stem cells may have different growth factor requirements. This is consistent with the hypothesis that fetal stem cells may be intrinsically different from adult stem cells, as speculated for tissues other than the hematopoietic tissue.39 Consequently, phenotypes of stem cells may vary during ontogeny. Adult bone marrow stained with the same reagents shows cells expressing CD34 levels as bright as those on fetal bone marrow CD34hi cells; however, the segregation between CD34hi and CD34'" subsets is not made easily on the basis of the CD34 expression alone, but requires staining for a second antigen such as CD38 or Thy-1I3 (our own observations). It remains to be demonstrated whether the long-term T, B, and myeloid activity can be exclusively retrieved in the CD34hi compartment of adult bone marrow.
We conclude from these studies that in fetal bone marrow that CD34 expression decreases with the commitment of hematopoietic progenitor cells to specific lineages and thus cells expressing the highest levels of CD34 are the most primitive. Of primary importance is the finding that, although the percentage of CD34hi cells among CD34+ population varies significantly, the staining intensity and biologic activities do not. Additionally, we were able to obtain enough cells for both in vitro and in vivo assays on most tissues, allowing correlations between in vivo and in vitro models to be made. Given these results, we have adopted the use of these cells and assays as standards for experimentation on stem cells, including genetic marking studies aimed at demonstrating self-renewal and multilineage potential of individual stem cells.
